Business Description
Bioporto AS
ISIN : DK0011048619
Total Employee Number:
46Description
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.3 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.47 | |||||
Beneish M-Score | -2.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.2 | |||||
3-Year EBITDA Growth Rate | 13.2 | |||||
3-Year EPS without NRI Growth Rate | 13.5 | |||||
3-Year FCF Growth Rate | 4.8 | |||||
3-Year Book Growth Rate | -14.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 51.23 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 15.5 | |||||
9-Day RSI | 26 | |||||
14-Day RSI | 35.04 | |||||
3-1 Month Momentum % | 63.19 | |||||
6-1 Month Momentum % | 32.23 | |||||
12-1 Month Momentum % | -4.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.25 | |||||
Quick Ratio | 2.9 | |||||
Cash Ratio | 2.1 | |||||
Days Inventory | 222.78 | |||||
Days Sales Outstanding | 74.96 | |||||
Days Payable | 305.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.5 | |||||
Shareholder Yield % | -14.38 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 75.44 | |||||
Operating Margin % | -213.7 | |||||
Net Margin % | -203.83 | |||||
EBITDA Margin % | -209.9 | |||||
FCF Margin % | -194.7 | |||||
OCF Margin % | -191.31 | |||||
ROE % | -155.17 | |||||
ROA % | -97.77 | |||||
ROIC % | -253.4 | |||||
3-Year ROIIC % | 212.35 | |||||
ROC (Joel Greenblatt) % | -820.42 | |||||
ROCE % | -148.02 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.23 | |||||
PB Ratio | 8.47 | |||||
Price-to-Tangible-Book | 6.48 | |||||
EV-to-EBIT | -5.87 | |||||
EV-to-EBITDA | -6.04 | |||||
EV-to-Forward-EBITDA | 5.76 | |||||
EV-to-Revenue | 12.67 | |||||
EV-to-Forward-Revenue | 11.63 | |||||
EV-to-FCF | -6.37 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Median-PS-Value | 0.65 | |||||
| Price-to-Net-Current-Asset-Value | 12.95 | |||||
| Price-to-Net-Cash | 12.95 | |||||
Earnings Yield (Greenblatt) % | -17.04 | |||||
FCF Yield % | -14.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bioporto AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.398 | ||
| EPS (TTM) (€) | -0.024 | ||
| Beta | 0.5763 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 53.06 | ||
| 14-Day RSI | 35.04 | ||
| 14-Day ATR (€) | 0.002749 | ||
| 20-Day SMA (€) | 0.1415 | ||
| 12-1 Month Momentum % | -4.25 | ||
| 52-Week Range (€) | 0.098 - 0.1886 | ||
| Shares Outstanding (Mil) | 495.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioporto AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bioporto AS Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-19 09:00 | In 141 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-19 | In 140 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 09:00 | In 50 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-20 | In 49 days | ||
| First quarter earnings conference call for 2026 | 2026-05-21 11:00 | 0.15 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-21 | 0.15 (+0.00%) | ||
| General meeting for 2025 | 2026-04-24 15:00 | 0.11 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 0.11 (+0.00%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-19 11:00 | 0.13 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 0.13 (+0.00%) |
Show
Entries
Bioporto AS Frequently Asked Questions
What is Bioporto AS(FRA:2P4)'s stock price today?
The current price of FRA:2P4 is €0.13. The 52 week high of FRA:2P4 is €0.19 and 52 week low is €0.10.
When is next earnings date of Bioporto AS(FRA:2P4)?
The next earnings date of Bioporto AS(FRA:2P4) is 2026-08-20.
Does Bioporto AS(FRA:2P4) pay dividends? If so, how much?
Bioporto AS(FRA:2P4) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer | 2023-10-17 |
Articles on Bioporto AS
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers